Clinical Trials

  • Principal Investigator:

    Stephanie Levasseur, MD
    The purpose of the study is to clarify the best treatment for your babys condition by looking at how well the medicine worked to bring your babys heart rate back to normal and if you experienced any side-effects from the treatment. You are being asked to take part in a research study because your fetus has been diagnosed with a fast heart rate. Although supraventricular tachycardia (SVT), including atrial flutter (AF), are the most common causes of intended in-utero fetal therapy, none of the medication used to date has been evaluated for their effects on the mother and her baby in a...
  • Principal Investigator:

    Vidhu Thaker, MD
    We are interested in studying the health of you and your family. Our study involves completing an online survey about your and your family's health and behaviors, and giving us access to basic health information that includes you and your child's vitals, weight/height, and BMI. You can receive up to $25 in Amazon pay cards for your participation. Spanish/English speakers who have a child 5 - 12 years of age are eligible to participate.
  • Principal Investigator:

    Alice Lee, MD
    The purpose of this study is to find the best dose of Palbociclib that can be given safely with chemotherapy in children and young adults with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) which has come back or has not responded to standard therapy. Palbociclib is considered experimental because it has not been approved by the United States (US) Food and Drug Administration (FDA) for treating children with Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL). Palbociclib works by targeting proteins that are necessary for cell growth. Palbociclib is given by...
  • Principal Investigator:

    Prakash Satwani, MD
    The main purpose of this research study is to determine if the experimental product, KTE-C19, when administered after you receive 3 days of chemotherapy, is safe and effective in treating your leukemia or non-Hodgkin lymphoma.
  • Principal Investigator:

    Prakash Satwani, MD
    The main purpose of this research study is to determine if the experimental product, KTE-C19, when administered after you receive 3 days of chemotherapy, is safe and effective in treating your leukemia or non-Hodgkin lymphoma.
  • Principal Investigator:

    Alice Lee, MD
    This is a Phase 1/2 multicenter study of lenvatinib administered in combination with everolimus inpediatric patients with relapsed or refractory solid tumors, including CNS tumors. The study treatment is considered experimental because lenvatinib is not approved by the United States(US) Food and Drug Administration (FDA) for treating pediatric patients with refractory solid tumors, including CNS tumors. The purpose of this study is to determine the highest safe dose of lenvatinib administered in combination with everolimus. Another objective is to study the effects of this combination of...
  • Principal Investigator:

    Nobuko Hijiya, MD
    This is a Phase 1 multicenter study of Vincristine Sulfate Liposome Injection (Marqibo) in combination with UK ALL R3 induction chemotherapy. The study treatment is considered experimental because it is not approved by the United States (US) Food and Drug Administration (FDA) for treating children with acute lymphoblastic leukemia (ALL) who have relapsed. The purpose of this study is to evaluate the toxicities and potential antitumor activity of Marqibo, given in combination with UK ALL R3 induction chemotherapy, in children with refractory ALL. Marqibo will be administered as an intravenous...
  • Principal Investigator:

    Alice Lee, MD
    This is a Phase 1 multicenter study of a drug called ABI-009 (nab-Rapamycin) in combination withtemozolomide and irinotecan in children and young adults with solid tumors (including CNS tumors)which have come back or have not responded to standard therapy. The study is considered experimental because ABI-009 (nab-Rapamycin) is not approved by the United States (US) Food and Drug Administration (FDA) for treating children and young adults with tumors, including CNS tumors. Both temozolomide and irinotecan are drugs that are FDA-approved for other indications. The purpose of this study is to...
  • Principal Investigator:

    Stergios Zacharoulis, MD
    The purpose of this study is to learn more about the treatment of children and young adults patient with relapsed (has returned) and progressive medulloblastoma (brain tumor). This study is being done to find out if bevacizumab can be safely given in combination with five study drugs given by mouth, thalidomide, fenofibrate, celecoxib and alternating every three weeks of etoposide and cyclophosphamide. Researchers want to evaluate whether the frequent delivery of low doses of study drugs chemotherapy will work for your cancer, while reducing the toxicity associated with standard dose...
  • Principal Investigator:

    Alice Lee, MD
    The purpose of this study is to find the best dose of Palbociclib that can be given safely with chemotherapy in children with solid tumor which has come back or has not responded to the standard therapy. Palbociclib works by targeting proteins that are necessary for cell growth. Palbociclib will be given by mouth on Days 1-14 of a 21-day cycle. It will be given in combination with chemotherapy drugs Irinotecan and Temozolomide.

Pages